Longevity & AgingSingle-Dose Epigenetic Therapy Enters Human Trials to Slash LDL Cholesterol
A biotech company called Scribe Therapeutics has received approval to test a new cholesterol-lowering treatment in humans for the first time. The therapy, STX-1150, uses a lipid nanoparticle to deliver genetic instructions into liver cells, silencing a gene called PCSK9 that controls LDL cholesterol levels. Unlike gene editing, this approach does not permanently change DNA — it works epigenetically, meaning it switches the gene off without rewriting it. The company says a single dose could produce long-lasting LDL reduction. Up to 64 adults with high cardiovascular risk will be enrolled across Australia and New Zealand, monitored for one year. This trial represents a potentially significant step toward durable, low-burden cardiovascular disease prevention.
